Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
UBS
Deloitte
Healthtrust
Cantor Fitzgerald
Medtronic
Merck
Cerilliant
Argus Health

Generated: December 12, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZIPRASIDONE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Ziprasidone Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00014001 CATIE- Schizophrenia Trial Completed National Institute of Mental Health (NIMH) Phase 4 The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate.
NCT00034801 Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia Completed Eli Lilly and Company Phase 4 This is a research study comparing the safety and efficacy of two active study medications
NCT00044655 Switching Medication to Treat Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00044655 Switching Medication to Treat Schizophrenia Completed Icahn School of Medicine at Mount Sinai Phase 4 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00048802 Treatment and Outcome of Early Onset Bipolar Disorder Completed National Institute of Mental Health (NIMH) Phase 4 This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
NCT00048802 Treatment and Outcome of Early Onset Bipolar Disorder Completed Northwell Health Phase 4 This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ziprasidone Hydrochloride

Condition Name

Condition Name for Ziprasidone Hydrochloride
Intervention Trials
Schizophrenia 65
Bipolar Disorder 35
Schizoaffective Disorder 20
Psychotic Disorders 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ziprasidone Hydrochloride
Intervention Trials
Schizophrenia 68
Disease 42
Psychotic Disorders 41
Bipolar Disorder 39
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ziprasidone Hydrochloride

Trials by Country

Trials by Country for Ziprasidone Hydrochloride
Location Trials
United States 473
India 23
Spain 23
Canada 23
Brazil 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ziprasidone Hydrochloride
Location Trials
New York 30
California 30
Ohio 24
Texas 22
Florida 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ziprasidone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Ziprasidone Hydrochloride
Clinical Trial Phase Trials
Phase 4 61
Phase 3 37
Phase 2/Phase 3 2
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ziprasidone Hydrochloride
Clinical Trial Phase Trials
Completed 100
Terminated 15
Recruiting 12
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ziprasidone Hydrochloride

Sponsor Name

Sponsor Name for Ziprasidone Hydrochloride
Sponsor Trials
Pfizer 72
National Institute of Mental Health (NIMH) 8
Massachusetts General Hospital 6
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ziprasidone Hydrochloride
Sponsor Trials
Other 127
Industry 93
NIH 10
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
QuintilesIMS
Boehringer Ingelheim
UBS
Baxter
Dow
Medtronic
Teva
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.